Agenus Secures Up to $340M Financing for Colon Cancer Trial, Shares Surge
Biotechnology firm Agenus announced a private placement of up to $340 million to advance its colon cancer immunotherapy trial. The funding includes an upfront $85 million and potential additional proceeds through warrants. This development has led to a 100% surge in the company's stock price.